clinical trial · NCT05884320
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
M.D. Anderson Cancer Center·phase2·recruiting·n = 30
GlandSalivary Gland CancersSacituzumab Govitecan
brief summary
To learn if sacituzumab govitecan can help to control salivary gland cancer.
started
Jul 27, 2023
primary completion
Jul 31, 2028
completion
Jul 31, 2028
last updated
Mar 20, 2026
detailed description
Primary Objectives:
* To assess the efficacy of SG in patients with R/M secretory gland carcinomas, specifically ACC (cohort 1) and SDC, adeno-NOS, and MEC (cohort 2)
Secondary Objectives:
* To estimate the median duration of response (DOR) * To estimate the median progression-free survival (PFS) * To estimate the median overall survival (OS) * To assess safety of SG
Tertiary / Exploratory Objectives:
* To explore biomarkers that may predict response to therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol